Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854-8020, USA; Taxis Pharmaceuticals Inc., North Brunswick, NJ, USA.
Bioorg Med Chem. 2013 Nov 1;21(21):6435-46. doi: 10.1016/j.bmc.2013.08.053. Epub 2013 Sep 4.
Inhibition of the endonuclease activity of influenza RNA-dependent RNA polymerase is recognized as an attractive target for the development of new agents for the treatment of influenza infection. Our earlier study employing small molecule fragment screening using a high-resolution crystal form of pandemic 2009 H1N1 influenza A endonuclease domain (PAN) resulted in the identification of 5-chloro-3-hydroxypyridin-2(1H)-one as a bimetal chelating ligand at the active site of the enzyme. In the present study, several phenyl substituted 3-hydroxypyridin-2(1H)-one compounds were synthesized and evaluated for their ability to inhibit the endonuclease activity as measured by a high-throughput fluorescence assay. Two of the more potent compounds in this series, 16 and 18, had IC50 values of 11 and 23nM in the enzymatic assay, respectively. Crystal structures revealed that these compounds had distinct binding modes that chelate the two active site metal ions (M1 and M2) using only two chelating groups. The SAR and the binding mode of these 3-hydroxypyridin-2-ones provide a basis for developing a new class of anti-influenza drugs.
抑制流感 RNA 依赖性 RNA 聚合酶的内切核酸酶活性被认为是开发治疗流感感染的新型药物的有吸引力的靶点。我们之前的研究采用小分子片段筛选方法,使用高分辨率的大流行性 2009 年 H1N1 流感 A 内切酶结构域(PAN)的晶体形式,鉴定出 5-氯-3-羟基吡啶-2(1H)-酮作为酶活性位点的双金属螯合配体。在本研究中,合成了几种取代的苯基 3-羟基吡啶-2(1H)-酮化合物,并评估了它们抑制内切核酸酶活性的能力,该活性通过高通量荧光测定法进行测量。在该系列中,两种更有效的化合物 16 和 18 的 IC50 值在酶测定中分别为 11 和 23nM。晶体结构表明,这些化合物具有独特的结合模式,仅使用两个螯合基团螯合两个活性位点金属离子(M1 和 M2)。这些 3-羟基吡啶-2-酮的 SAR 和结合模式为开发新型抗流感药物提供了基础。